A common molecular pathway could help physicians predict which lung cancer patients will benefit from chemotherapy drugs, according to new research from a multidisciplinary team at the University of Cincinnati (UC).
Known as the retinoblastoma (RB) tumor suppressor, this fundamental molecule regulates cell proliferation in the body. Research has shown that the RB pathway is either entirely inactive or altered in most human cancers. Scientists are beginning to use its actions as a “biomarker” for how tumors will respond to different therapies.